Obesity and insulin resistance: Pathophysiology and treatment

Drug Discov Today. 2022 Mar;27(3):822-830. doi: 10.1016/j.drudis.2021.11.001. Epub 2021 Nov 9.

Abstract

The prevalence of obesity is a major cause of many chronic metabolic disorders, including type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), and cancer. Insulin resistance is often associated with metabolic unhealthy obesity (MUO). Therapeutic approaches aiming to improve insulin sensitivity are believed to be central for the prevention and treatment of MUO. However, current antiobesity drugs are reported as multitargeted and their insulin-sensitizing effects remain unclear. In this review, we discuss current understanding of the mechanisms of insulin resistance from the aspects of endocrine disturbance, inflammation, oxidative, and endoplasmic reticulum stress (ERS). We then summarize the antiobesity drugs, focusing on their effects on insulin sensitivity. Finally, we discuss strategies for obesity treatment.

Keywords: Anti-obesity drugs; Insulin sensitivity; Obesity.

Publication types

  • Review

MeSH terms

  • Anti-Obesity Agents* / therapeutic use
  • Diabetes Mellitus, Type 2* / drug therapy
  • Humans
  • Insulin / metabolism
  • Insulin Resistance*
  • Obesity / drug therapy
  • Obesity / metabolism

Substances

  • Anti-Obesity Agents
  • Insulin